Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 27 peer-reviewed journal articles Updated
Oncology

Prognosis & The Road Ahead: Monitoring for the Long Term

At a Glance

Life after PTLD treatment requires balancing the prevention of cancer relapse with keeping your transplanted organ healthy. Your monitoring plan will likely include regular EBV viral load blood tests, specific symptom checks, and potentially switching to mTOR inhibitor medications.

Finishing treatment for PTLD is a major milestone, but it often marks the beginning of a new, complex chapter. You are now balancing two lifelong priorities: preventing the PTLD from coming back (relapse) and keeping your transplanted organ healthy (graft preservation) [1][2]. Understanding how your risk is measured and how you will be monitored can help replace “scan anxiety” with a sense of proactive control [3].

Measuring Risk: The Scoring Systems

Doctors use “risk scores” to predict how PTLD might behave and to guide how aggressively they should monitor you. Two common tools are:

  • The International Prognostic Index (IPI): Originally designed for standard lymphomas, the IPI looks at five factors: being over age 60, having advanced stage disease (III or IV), high LDH levels in the blood, poor overall physical “performance status,” and disease in more than one organ outside the lymph system [4][5].
  • The LT-PTLD Score: This specialized tool is often used for adult solid organ transplant recipients. It scores risk based on three factors at diagnosis: age (18 or older), poor physical performance status, and having the monomorphic subtype of PTLD [6]. Note for parents: Risk scoring for children relies less on these adult-focused tools and more on factors like EBV status, how much the disease has spread, and the specific subtype.

In general, patients with “early lesions” or “polymorphic” PTLD tend to have a better long-term outlook than those with the “monomorphic” or “Hodgkin-like” types [7][8].

Long-Term Surveillance: The “Road Ahead”

Because there is no single “one-size-fits-all” schedule for PTLD survivors, your monitoring plan will be tailored to your specific risk level [3][9].

1. EBV Viral Load Monitoring

This is the most frequent part of your follow-up. Using a blood test, doctors count the “viral load” of the Epstein-Barr Virus (EBV) [10].

  • The Goal: A rising viral load can sometimes act as an “early warning system” that the virus is waking up again [3][11].
  • The Reality: Some survivors have a “chronic low-level” viral load that never causes problems. A high viral load does not always mean the PTLD is back, but it does mean your team needs to stay vigilant [12][13].

2. Imaging (PET/CT Scans)

PET/CT scans are highly sensitive at finding active PTLD cells by looking for areas that “eat” radioactive sugar [14][15].

  • The Pitfall: PET scans can show “hot spots” for many reasons other than cancer, including simple infections or even the body’s reaction to a recent vaccine [16][17].
  • The Schedule: There is no universal rule for how often you should get a scan once you are in remission; many doctors only order them if your symptoms or blood tests change [18].

Living with “Dual Risk”

The psychological toll of PTLD is unique because you are managing two different types of fear. If you strengthen the immune system to fight cancer, you risk organ rejection. If you suppress it too much to protect the organ, you risk the cancer returning [1][19].

  • Medication Adjustments: Some survivors are switched to a class of drugs called mTOR inhibitors (like Sirolimus or Everolimus). These medications are unique because they help prevent organ rejection while also having some anti-cancer properties [20][21].
  • Self-Monitoring: While you should not obsess over every ache, you should report “B-symptoms” (fever, night sweats, unexplained weight loss) or new pain near your transplant organ immediately [22][23].
  • Psychological Support: “Scanxiety”—the intense fear before a follow-up test—is common. Seeking a therapist who specializes in chronic illness or transplant-related trauma can be a vital part of your recovery [24].

Remember, survival for PTLD has improved significantly in the modern era, and many survivors go on to live long, healthy lives with their original transplant [25][26]. Areas of PTLD research, such as cellular therapies, continue to provide new “safety nets” for the future [27].

Common questions in this guide

What is the LT-PTLD risk score?
The LT-PTLD score is a tool used by doctors to predict how the disease might behave in adult solid organ transplant recipients. It evaluates age, physical performance status, and your specific disease subtype at diagnosis to guide your long-term monitoring strategy.
What does a high EBV viral load mean after PTLD treatment?
A rising Epstein-Barr Virus (EBV) viral load can sometimes be an early warning sign that the virus is becoming active again. However, some survivors maintain a chronic low-level viral load without issues, so a high result does not automatically mean the disease has returned.
How often will I need PET scans after PTLD treatment?
There is no universal schedule for PET scans once you are in remission. Because scans can show false positives from infections or vaccines, many doctors only order them if you develop new symptoms or if your blood tests show concerning changes.
Can my anti-rejection medications help prevent a PTLD relapse?
Yes, doctors sometimes switch survivors to a type of anti-rejection medication called mTOR inhibitors, such as Sirolimus or Everolimus. These drugs are unique because they help protect your transplanted organ while also providing anti-cancer effects.
What are the signs of a PTLD relapse that I should watch for?
You should immediately report B-symptoms to your healthcare team, which include fever, night sweats, and unexplained weight loss. You should also watch for any new pain near your transplanted organ or the appearance of new lumps.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my (or my child's) age, disease stage, and subtype, what was my 'IPI' or 'LT-PTLD' risk score at diagnosis?
  2. 2.Now that treatment is finished, what is our specific 'monitoring plan' for the next two years? How often will we test my EBV viral load?
  3. 3.If my EBV viral load starts to rise but I feel fine, what is the next step? Do we change medications or wait for a scan?
  4. 4.Is it possible to switch my anti-rejection medicine to an mTOR inhibitor (like Sirolimus) to help lower the risk of the PTLD coming back?
  5. 5.How will we know the difference between a PTLD relapse and a simple infection on my future PET/CT scans?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (27)
  1. 1

    Successful Treatment of Ocular Post-Transplant Lymphoproliferative Disorder with Obinutuzumab in an 8-Year-Old Boy Following Kidney Transplant: A Case Report.

    Lussier C, Larche CL, Vadboncoeur J

    Ocular immunology and inflammation 2025; (33(7)):1483-1488 doi:10.1080/09273948.2025.2495070.

    PMID: 40255019
  2. 2

    Incidence and mortality of post-transplant lymphoproliferative disorders after kidney transplantation: A real-world retrospective analysis in Japan.

    Kato T, Yoshida T, Taniguchi A, et al.

    International journal of urology : official journal of the Japanese Urological Association 2022; (29(3)):206-211 doi:10.1111/iju.14750.

    PMID: 34897833
  3. 3

    Incidence and Timing of Epstein-Barr Virus Whole Blood DNAemia in Epstein-Barr Virus-Mismatched Adult and Pediatric Solid Organ Transplant Recipients.

    Burton C, Mabilangan C, Preiksaitis J

    Transplant infectious disease : an official journal of the Transplantation Society 2025; (27(4)):e70042 doi:10.1111/tid.70042.

    PMID: 40298363
  4. 4

    Failure of rituximab is associated with a poor outcome in diffuse large B cell lymphoma-type post-transplant lymphoproliferative disorder.

    Jain MD, Lam R, Liu Z, et al.

    British journal of haematology 2020; (189(1)):97-105 doi:10.1111/bjh.16304.

    PMID: 32068243
  5. 5

    Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era.

    Seo S, Hong JY, Yoon S, et al.

    Oncotarget 2016; (7(47)):76934-76943 doi:10.18632/oncotarget.12734.

    PMID: 27764777
  6. 6

    Post-transplant Lymphoproliferative Disorders After Liver Transplantation: A Retrospective Cohort Study Including 1954 Transplants.

    Tajima T, Hata K, Haga H, et al.

    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2021; (27(8)):1165-1180 doi:10.1002/lt.26034.

    PMID: 33655645
  7. 7

    Relationship of Post-Transplant Lymphoproliferative Disorders (PTLD) Subtypes and Clinical Outcome in Pediatric Heart Transplant Recipients: A Retrospective Single Institutional Analysis/Experience of 558 Patients.

    Liu Y, Wang BC, Zuppan CW, et al.

    Cancers 2023; (15(3)) doi:10.3390/cancers15030976.

    PMID: 36765933
  8. 8

    Relationship between rabbit anti-thymocyte globulin and development of PTLD and its aggressive form in renal transplant population.

    Ali H, Soliman K, Daoud A, et al.

    Renal failure 2020; (42(1)):489-494 doi:10.1080/0886022X.2020.1759636.

    PMID: 32423337
  9. 9

    Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.

    Allen UD, Preiksaitis JK,

    Clinical transplantation 2019; (33(9)):e13652 doi:10.1111/ctr.13652.

    PMID: 31230381
  10. 10

    Epstein-Barr virus-positive lymphoproliferative disorder manifesting as pulmonary disease in a patient with acute myeloid leukemia: a case report.

    Dutta R, Miao SY, Phan P, et al.

    Journal of medical case reports 2021; (15(1)):170 doi:10.1186/s13256-021-02744-2.

    PMID: 33773605
  11. 11

    Use of Rituximab for persistent EBV DNAemia, and Its effect on donor-specific antibody development in pediatric renal transplant recipients: A case series.

    Puliyanda DP, Jordan SC, Kim IK, et al.

    Pediatric transplantation 2021; (25(8)):e14113 doi:10.1111/petr.14113.

    PMID: 34418254
  12. 12

    Central nervous system post-transplant lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation: The Nagasaki transplant group experience.

    Sakamoto H, Itonaga H, Taguchi J, et al.

    Leukemia research reports 2019; (11()):27-30 doi:10.1016/j.lrr.2019.04.003.

    PMID: 31049285
  13. 13

    Epstein Barr Virus Quantitative Polymerase Chain Reaction Monitoring in Lung and Bone Marrow Transplant Patients to Predict Post-Transplant Lymphoproliferative Disorder: A Systematic Review.

    Divithotawela C, Lee SZ, Schulz M, Chambers DC

    Transplantation proceedings 2025; (57(5)):931-939 doi:10.1016/j.transproceed.2025.03.008.

    PMID: 40316451
  14. 14

    18F-FDG PET/CT is an ideal imaging modality for the early diagnosis of relapsing polychondritis: A case report.

    Wang J, Liu X, Pu C, Chen Y

    Medicine 2017; (96(30)):e7503 doi:10.1097/MD.0000000000007503.

    PMID: 28746194
  15. 15

    18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Scan in an Unusual Case of Lymphoma with Secondary Involvement of Uterine Cervix Presenting as a Pathological Fracture.

    Sasikumar A, Joy A, Pillai MR, Thomas B

    Indian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, India 2017; (32(1)):54-56 doi:10.4103/0972-3919.198483.

    PMID: 28242988
  16. 16

    Extrapulmonary Tuberculosis Mimicking Malignancy.

    Güneren C, Uslu Beşli RL, Sayman HB

    Molecular imaging and radionuclide therapy 2025; doi:10.4274/mirt.galenos.2025.43925.

    PMID: 41414703
  17. 17

    18F-fluorodeoxyglucose positron emission tomography/computed tomography in the diagnosis of benign pulmonary lesions in sarcoidosis.

    Zhao M, Xin XF, Hu H, et al.

    Translational lung cancer research 2019; (8(3)):208-213 doi:10.21037/tlcr.2019.06.09.

    PMID: 31367534
  18. 18

    Posttransplant Lymphoproliferative Disorder Following Kidney Transplantation: A Review.

    Sprangers B, Riella LV, Dierickx D

    American journal of kidney diseases : the official journal of the National Kidney Foundation 2021; (78(2)):272-281 doi:10.1053/j.ajkd.2021.01.015.

    PMID: 33774079
  19. 19

    Multisite Head and Neck Pediatric Posttransplant Lymphoproliferative Disorder: A Case Report.

    Gao L, Hoke A, Jackson J, et al.

    Clinical case reports 2025; (13(2)):e70200 doi:10.1002/ccr3.70200.

    PMID: 39959555
  20. 20

    Survival of Post-Transplant Lymphoproliferative Disorder after Kidney Transplantation in Patients under Rapamycin Treatment.

    Ashrafi F, Shahidi S, Mehrzad V, et al.

    International journal of hematology-oncology and stem cell research 2021; (15(4)):239-248 doi:10.18502/ijhoscr.v15i4.7479.

    PMID: 35291663
  21. 21

    Short-term decreased post transplant lymphoproliferative disorder risk after kidney transplantation using two novel regimens.

    Chiodo Ortiz A, Petrossian G, Addonizio K, et al.

    Transplant immunology 2023; (76()):101774 doi:10.1016/j.trim.2022.101774.

    PMID: 36528248
  22. 22

    COVID-19 and Superimposed Aspergillosis in a Dual Organ Recipient with Diagnosed B-Cell Lymphoproliferative Disorder: A Rare Case Report and Literature Review.

    Karadžić-Ristanović V, Pavlović J, Brković V, et al.

    Diseases (Basel, Switzerland) 2025; (13(10)) doi:10.3390/diseases13100339.

    PMID: 41149073
  23. 23

    Posttransplant Lymphoproliferative Disorder Status Post-Solid Organ Transplant Presenting to the Emergency Department: Single Institute Experience.

    Rao S, Smith DA, Kikano EG, et al.

    Journal of computer assisted tomography 2021; (45(6)):894-903 doi:10.1097/RCT.0000000000001212.

    PMID: 34347710
  24. 24

    Posttransplant Lymphoproliferative Disorder After Solid Organ Transplant: A Heterogeneous, Aggressive Disorder.

    McDonald L, O' Doherty R, Ryan E, et al.

    Clinical lymphoma, myeloma & leukemia 2021; (21(10)):694-700 doi:10.1016/j.clml.2021.05.009.

    PMID: 34148849
  25. 25

    Post-transplant lymphoproliferative disease may be an adverse risk factor for patient survival but not graft loss in kidney transplant recipients.

    Francis A, Johnson DW, Craig J, et al.

    Kidney international 2018; (94(4)):809-817 doi:10.1016/j.kint.2018.06.009.

    PMID: 30173897
  26. 26

    Characteristics and Outcome of Post-Transplant Lymphoproliferative Disorders After Solid Organ Transplantation: A Single Center Experience of 196 Patients Over 30 Years.

    Vergote VKJ, Deroose CM, Fieuws S, et al.

    Transplant international : official journal of the European Society for Organ Transplantation 2022; (35()):10707 doi:10.3389/ti.2022.10707.

    PMID: 36589262
  27. 27

    Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial.

    Mahadeo KM, Baiocchi R, Beitinjaneh A, et al.

    The Lancet. Oncology 2024; (25(3)):376-387 doi:10.1016/S1470-2045(23)00649-6.

    PMID: 38309282

This page explains PTLD monitoring and prognosis for educational purposes only. Always consult your transplant and oncology teams regarding your specific risk factors, follow-up schedule, and medication management.

Get notified when new evidence is published on Post-transplant lymphoproliferative disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.